[
  {
    "variant_string_id": "alpha-synuclein A53T",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "alpha-synuclein (α-syn) is strongly implicated in the pathogenesis of Parkinson’s disease (PD) and other synucleinopathies. Mutations in α-syn can lead to increased aggregation and neurotoxicity.",
        "judgment": "Yes",
        "reasoning": "The paper clearly states that alpha-synuclein is implicated in PD and mutations lead to aggregation and neurotoxicity, establishing a link between the gene's function and the disease's underlying mechanisms.",
        "next_step_or_outcome": "Proceed to Step 5"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "We investigated the effects of the A53T mutation using in vitro aggregation assays and cell-based assays to assess toxicity.",
        "judgment": "Yes",
        "reasoning": "Aggregation and toxicity assays are standard approaches to study alpha-synuclein mutations and are applicable to evaluate the disease mechanism.",
        "next_step_or_outcome": "Proceed to Step 4"
      },
      {
        "step_name": "Sub-step 3a: Basic Controls and Replicates.",
        "extracted_paper_info": "Experiments were performed in triplicate, and each condition was compared to a wild-type α-synuclein control.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly states that experiments were performed in triplicate and included wild-type controls, meeting the requirements for basic controls and replicates.",
        "next_step_or_outcome": "Proceed to Step 1"
      },
      {
        "step_name": "Sub-step 3c: Variant Controls",
        "extracted_paper_info": "We did not use other variants in this study",
        "judgment": "No",
        "reasoning": "The paper does not state the usage of other pathogenic or benign variants to compare against the A53T variant.",
        "next_step_or_outcome": "Proceed to Step 2"
      }
    ]
  }
]